Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Accounts Payables: 2011-2024

Historic Accounts Payables for Niagen Bioscience (NAGE) over the last 11 years, with Dec 2024 value amounting to $8.5 million.

  • Niagen Bioscience's Accounts Payables rose 84.59% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 84.59%. This contributed to the annual value of $8.5 million for FY2024, which is 16.67% down from last year.
  • According to the latest figures from FY2024, Niagen Bioscience's Accounts Payables is $8.5 million, which was down 16.67% from $10.2 million recorded in FY2023.
  • Over the past 5 years, Niagen Bioscience's Accounts Payables peaked at $10.4 million during FY2021, and registered a low of $8.5 million during FY2024.
  • Moreover, its 3-year median value for Accounts Payables was $9.7 million (2022), whereas its average is $9.5 million.
  • Per our database at Business Quant, Niagen Bioscience's Accounts Payables climbed by 10.35% in 2021 and then dropped by 16.67% in 2024.
  • Niagen Bioscience's Accounts Payables (Yearly) stood at $9.4 million in 2020, then climbed by 10.35% to $10.4 million in 2021, then decreased by 7.14% to $9.7 million in 2022, then rose by 5.71% to $10.2 million in 2023, then declined by 16.67% to $8.5 million in 2024.